相似文献
1
BNP and Precision Medicine: Tip of an Iceberg.
JACC Basic Transl Sci. 2021 Jun 28;6(6):505-506. doi: 10.1016/j.jacbts.2021.05.007. eCollection 2021 Jun.
2
Diagnosis of heart failure using urinary natriuretic peptides.
Clin Sci (Lond). 2004 Feb;106(2):129-33. doi: 10.1042/CS20030234.
3
Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Circ Heart Fail. 2020 Feb;13(2):e006541. doi: 10.1161/CIRCHEARTFAILURE.119.006541. Epub 2020 Feb 17.
4
[Natriuretic peptides--new diagnostic markers in heart disease].
Herz. 2004 Sep;29(6):609-17. doi: 10.1007/s00059-004-2619-8.
5
Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.
Ont Health Technol Assess Ser. 2021 May 6;21(2):1-125. eCollection 2021.
6
Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate.
Eur J Heart Fail. 2003 Oct;5(5):599-606. doi: 10.1016/s1388-9842(03)00108-9.
7
A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure.
Arch Intern Med. 2004 Oct 11;164(18):1978-84. doi: 10.1001/archinte.164.18.1978.
8
Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.
Pharmacol Ther. 2004 Jun;102(3):223-41. doi: 10.1016/j.pharmthera.2004.04.004.
9
Atrial and brain natriuretic peptides: Hormones secreted from the heart.
Peptides. 2019 Jan;111:18-25. doi: 10.1016/j.peptides.2018.05.012. Epub 2018 May 31.
10
Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Mol Pharmacol. 2010 Sep;78(3):431-5. doi: 10.1124/mol.110.066084. Epub 2010 Jun 8.
引用本文的文献
1
Natriuretic peptide pathways in heart failure: further therapeutic possibilities.
Cardiovasc Res. 2023 Feb 3;118(18):3416-3433. doi: 10.1093/cvr/cvac125.
2
Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension.
Front Physiol. 2022 Feb 11;12:815796. doi: 10.3389/fphys.2021.815796. eCollection 2021.
本文引用的文献
1
STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure.
JACC Basic Transl Sci. 2021 Jun 16;6(6):497-504. doi: 10.1016/j.jacbts.2021.05.001. eCollection 2021 Jun.
2
Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort.
Europace. 2020 Oct 1;22(10):1463-1469. doi: 10.1093/europace/euaa158.
3
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure.
Nat Commun. 2020 Jan 9;11(1):163. doi: 10.1038/s41467-019-13690-5.
4
Natriuretic Peptide Deficiency-When There Is Too Little of a Good Thing.
JAMA Cardiol. 2018 Jan 1;3(1):7-9. doi: 10.1001/jamacardio.2017.4208.
5
An Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality.
J Am Heart Assoc. 2017 Mar 24;6(4):e005257. doi: 10.1161/JAHA.116.005257.
6
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure.
Nat Genet. 2009 Mar;41(3):348-53. doi: 10.1038/ng.328. Epub 2009 Feb 15.
Zotero 插件